pharmaphorum

MAY 23, 2022

A study that will look at the feasibility of tracking people’s lifestyle habits for an extended period using a wearable device has got underway in Japan, backed by drugmakers Takeda and Daiichi Sankyo. The device will be worn by 2,000 people for a year, harvesting data on sleep status, heart rate, and activity levels, according to the study partners, which also include digital health and telemedicine firm MICIN and Tohoku University.

90

90

Pharma Marketing Network

MAY 23, 2022

Tune in to this episode of the Pharma Marketing Podcast with Bharti Rai, Novartis VP, Chief Commercial Operations, Insight, Analytics Officer Data & Digital, for a deeper dive into what’s ahead for 1st and 3rd party data, insights, analytics & digital data. The post Bharti Rai, Novartis VP & Head of Commercial Acceleration on What’s Ahead for 1st and 3rd party data, Insights, Analytics & Digital Data appeared first on Pharma Marketing Network.

52

52

pharmaphorum

MAY 23, 2022

This article follows part one of our two-part series, in which we discussed how USAID invests in digital infrastructure as part of its development and humanitarian assistance programmes. . Adele Waugaman, senior digital health coordinator of the COVID-19 response at the United States Agency for International Development (USAID), discusses the value of establishing donor partnerships and how those collaborations can improve digital health options globally. .

Pharmaceutical Companies 100

Pharmaceutical Companies Pharmaceutical Companies Communication Vaccines 100

Outsourcing Pharma

MAY 23, 2022

With Veeva Link for Key People, LEO Pharma is looking to deepen its efforts to engage with knowledgeable medical professionals in the dermatology community.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MAY 23, 2022

AbbVie has filed for approval of its therapy for Parkinson’s disease, ABBV-951, which promises continuous control of symptoms and would be an alternative to current drugs that often fail to control symptoms throughout a 24-hour period. ABBV-951 is based on foslevodopa and foscarbidopa – prodrugs of two widely-used oral Parkinson’s drugs – and is delivered via a subcutaneous pump once a day.

52

52

Pharma Times

MAY 23, 2022

It is the first gene therapy to be directly administered into the brain to treat aromatic L-amino acid decarboxylase (AADC) deficiency

49

49

Pharma Manufacturing

MAY 23, 2022

For pharma, picking the right partner can have an enormous impact on project outcomes

40

40

pharmaphorum

MAY 23, 2022

Sanofi’s Genzyme unit has moved a step closer to securing EU approval for Xenpozyme – its enzyme replacement therapy for rare disease acid sphingomyelinase deficiency (ASMD) – after scoring a positive opinion from the CHMP. Xenpozyme (olipudase alfa) is set to become the first and only approved therapy for ASMD type A/B or ASMD type B, two forms of a group of genetic disorders also known as Niemann-Pick disease in which fats build up within cells, causing them to die and disrupting tissue

52

52

Pharma Manufacturing

MAY 23, 2022

Andrea Corona is joined by Zach Gilulah, pharma machine health lead at Augury.

40

40

Pharma Times

MAY 23, 2022

Positive opinion is based on data from clinical trials which showed improvement in lung function

41

41

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

MAY 23, 2022

PTC Therapeutic’s Upstaza gene therapy for patients with genetic disorder AADC deficiency has been recommended for approval in the EU, setting up another test of the commercial prospects for gene therapies in the bloc. Once full approval is granted Upstaza (eladocagene exuparvovec) will become the first disease-modifying treatment for AADC (aromatic L-amino acid decarboxylase) deficiency, as well as the first gene therapy directly administered into the brain, said PTC.

100

100

pharmaphorum

MAY 23, 2022

Telehealth company Amwell has marked Mental Health Awareness month with the launch of a digital tool that will deliver cognitive behavioural health interventions across a spectrum of mental illness. The suite – which combines virtual therapy and psychiatry, optional coaching, and digital mental health programmes tailored to the patient’s needs – has been developed in the wake of Amwell’s acquisition last year of SilverCloud Health.

87

87